Canine tear proteomics gains traction in ophthalmology

A new Veterinary Ophthalmology review, “Canine Tear Proteomics: A New Frontier in Veterinary Ophthalmology,” makes the case that tear-based protein analysis could become an important next chapter in canine eye care. The review frames tears as a practical diagnostic sample: easy to collect, minimally invasive, and biologically rich, with proteins tied to ocular surface protection, inflammation, immune defense, and signaling. In dogs, the authors say, that makes tear proteomics relevant not only for ophthalmic disease, but also for comparative biomedical research. (pmc.ncbi.nlm.nih.gov)

That argument builds on nearly two decades of incremental work. Earlier studies established baseline maps of the normal canine tear proteome, giving researchers a starting point for comparing healthy and diseased eyes. From there, the literature expanded into disease-specific applications, including work on canine keratoconjunctivitis sicca, glaucoma, and even potential cancer-associated tear markers. At the same time, the broader ophthalmology field has been pushing tear proteomics as a route toward non-invasive biomarker discovery and, eventually, more precise diagnostics. (pubmed.ncbi.nlm.nih.gov)

The strongest canine evidence so far appears to be in dry eye and ocular surface disease. A recent KCS study found distinct shifts in tear proteins, including increases in higher-molecular-weight proteins and loss of some low-molecular-weight components, suggesting disruption of tear film homeostasis and ocular surface defense. Another study reported that protein-expression changes after topical cyclosporine A treatment could help track disease severity and treatment effectiveness, with inflammatory proteins such as S100-A12 flagged as candidate biomarkers. Together, those findings support the review’s central point: tear proteomics may offer more than description, potentially helping clinicians monitor biologic response over time. (pmc.ncbi.nlm.nih.gov)

Still, the technical caveats are important. Research groups have shown that how tears are collected can meaningfully change the protein profile that is measured. In one canine study, microcapillary tubes, Schirmer tear strips, and ophthalmic sponges produced different expression patterns, even when total protein concentrations were not significantly different. Another study found disease state affected tear protein levels, while diurnal variation did not appear to be a major factor. For clinicians and researchers, that means promising biomarker signals could be undermined if sample collection and processing are not standardized. (pubmed.ncbi.nlm.nih.gov)

Outside veterinary medicine, expert commentary has been consistently optimistic, but cautious, about translation. A widely cited perspective in Expert Review of Proteomics said tear ‘omics’ could support patient stratification and precision medicine because collection is fast, safe, and non-invasive, and because proteomic discoveries may eventually be converted into clinical assays. More recent expert commentary on tear biomarkers has similarly focused on the gap between discovery and point-of-care use, emphasizing the need for validation, reproducibility, and clinically practical platforms. That broader message fits the canine literature well: the science is advancing, but routine use will depend on assay development and external validation. (tandfonline.com)

Why it matters: For veterinary ophthalmologists and general practitioners, tear proteomics is compelling because it could add objective molecular data to diseases that are often monitored through a combination of clinical signs, tear testing, staining, tonometry, and response to treatment. In conditions like KCS, where severity, inflammation, and treatment response can vary, a validated tear biomarker panel could eventually help refine diagnosis, monitor progression, or identify earlier biologic change than conventional exams alone. It may also widen the role of the dog as a translational model for human ocular surface disease and glaucoma research, which could accelerate method development on both sides of the species line. (pmc.ncbi.nlm.nih.gov)

The opportunity, though, shouldn’t be overstated. Most canine tear proteomics work remains exploratory, small-scale, or method-focused, and there is not yet a standardized clinical test available for veterinary practice based on these findings. For now, the review is best read as a marker of momentum: the field has moved beyond cataloging proteins and is starting to identify disease-linked patterns that could matter in practice if they hold up in larger, prospective studies. (pmc.ncbi.nlm.nih.gov)

What to watch: The next phase will likely center on validation studies, harmonized collection protocols, and targeted assays that can test a short list of clinically meaningful proteins in real-world canine ophthalmology settings. If that happens, tear proteomics could shift from a research tool to a useful adjunct in managing chronic ocular surface disease, glaucoma, and possibly systemic disease with ocular signatures. (pubmed.ncbi.nlm.nih.gov)